# A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.

> **NCT02726334** · PHASE1 · TERMINATED · sponsor: **Bionomics Limited** · enrollment: 22 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** BNC101 Solution for Infusion
- **DRUG:** BNC101 in combination with FOLFIRI

## Key facts

- **NCT ID:** NCT02726334
- **Lead sponsor:** Bionomics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2017-12
- **Final completion:** 2018-02
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Monotherapy arm completed. Combination arm did not proceed (sponsor decision).
- **Last updated:** 2019-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02726334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02726334, "A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02726334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*